We use cookies to ensure the best user experience. By using the page, you accept the usage of cookies.
Read more about cookies
OK
Skip to Content
Open or close main menu
FI
SV
SV
Sidan finns inte på svenska.
Tillbaka till den svenskspråkiga förstasidan av fimea.fi.
Ångra
EN
Close navigation
Front page
For public
Open or close sub-menu
Databases and registers
Open or close sub-menu
Development and HTA
Open or close sub-menu
Marketing Authorisations
Open or close sub-menu
Medical devices
Open or close sub-menu
Pharmaceutical safety and information
Open or close sub-menu
Pharmacies
Open or close sub-menu
Supervision
Open or close sub-menu
Veterinary
Open or close sub-menu
About us
Open or close sub-menu
Contact us
Open or close sub-menu
Coronavirus (COVID-19)
Open or close sub-menu
What's new
Open or close sub-menu
Open positions
Forms
Organisation
Open or close sub-menu
Publications
Fees
Estimated processing times
Frequently asked questions
Open or close sub-menu
Clinical drug trials
Generic medicines
Invoicing
Marketing authorisations
Open or close sub-menu
Narcotics control
New EudraVigilance -system
Open data
SearchBar
page search
page search
medicine search
Choose search type
page search
medicine search
Search from site...
Search
Search
Search field
med-button-search
i
Move to advanced medicine search
openSearch
Medicine search
Contact Information
FI
SV
SV
Sidan finns inte på svenska.
Tillbaka till den svenskspråkiga förstasidan av fimea.fi.
Ångra
EN
fimea.fi
For public
Fimea’s services to citizens
Cooperation with patient associations
What is a medicine?
Generic substitution
Generic products
What is a food supplement?
Safety of medicines
Monitoring the safety of medicinal products
Adverse reactions
Submitting a report on an adverse reaction
Medicinal products under additional monitoring
Product defects
Drug interactions
Pharmaceutical injuries
Correct use of medicines
Ensure the safety of your medication
Monitor the effects of your medication
How to store medicines?
How should medicines be disposed of?
List of medicines
Where can I find reliable information about medicines?
How can I assess the reliability of drug information?
Medicinal product packs
Package leaflet
How are medicines supplied to users in Finland?
What factors affect the availability of medicines?
Why might a pharmacy run out of my medicine?
Obligatory storing of medicines
Exemptions and special permits
Ordering medicines online
Why is the food supplement I ordered considered to be a medicine?
Bringing medicines to Finland
What medicines can I bring abroad?
Falsified medicines
Pain relievers and self-care
Medicines and pregnancy
Medicines for children
Developing better medicines for children
Medication of the elderly
Vaccines
Influenza
Influenza vaccinations
Antiviral medication
Pandemic
Databases and registers
FimeaWeb
Meds75+
Consumption
Self-medication products
Basic register
Plasma-derived products with marketing authorisation
Substitutable medicinal products
Textfile for databases
Criteria used in compiling the list
Consumption information
ATC codes
Shortages
Development and HTA
Assessment of pharmacotherapies (HTA)
Assessment of hospital-only medicinal products
Topic selection
Nordic collaboration (FINOSE)
Assessment reports (in Finnish)
Research
Research Network for Rational Pharmacotherapy (RATTI)
Medicines information
Medicines Information Network
High-quality medicines information
Interprofessional network
Patient advisory board
Marketing Authorisations
Marketing authorisation application
Finland as a Reference Member State in the decentralised procedure (DCP)
Finland as a Reference Member State in the Mutual Recognition / Repeat Use Procedure (MRP/RUP)
Changing of Reference Member State duties to Finland
Finland as a rapporteur in the centralised marketing authorisation procedure (CP)
Granted and cancelled marketing authorisations
Pending marketing authorisation applications
Biological Medicinal Products
Orphan drugs
Paediatric medicines
European Pharmacopoeia
Active substance names and standard terms
Renewals and variation applications
Renewals
Variation applications
Changes to labelling
Transferring a marketing authorisation to a new holder
Article 5 classification requests for variation applications
OTC application
Product Information
Summary of product characteristics
Package leaflet
Package labelling
Text templates
Braille and package leaflets for the visually impaired
Trade names of medicinal products
Strength
Translating influenza vaccines in Finland
Electronic marketing authorisation submissions
What's new
Instructions for electronic marketing authorisation submissions
Special characteristics of the electronic marketing authorisation process for veterinary medicines
Cancelling a marketing authorisation or registration and sunset clause
Cancelling a marketing authorisation or registration
Expiration of marketing authorisations and registrations (sunset clause)
Sunset clause - concepts
Sunset clause exemption
List of expired marketing authorisations and registrations
Introduction to market and shortage notifications
Parallel import
Herbal remedies and medicinal products
Herbal medicinal products
Traditional herbal medicinal products
Homeopathic and anthroposophic preparations
Innovation Office
Informal Regulatory Guidance
Scientific Advice
Interchangeable medicinal products
Safety features
Other permits
Exemption
Frequently asked questions - marketing authorisations
Summary of Product Characteristics is to be available also in Swedish
Local representative
Medical devices
Export
Legislation
Placing on the market
Clinical investigation
Registration
Incident reporting
Language requirements
Brexit and the availability of medical devices
Market surveillance programmes
Pharmaceutical safety and information
Pharmaceutical safety
Reporting adverse reactions
Biological medicinal products
Biosimilars
Biosimilars in Finland
Regulation on Medicinal Products for Paediatric Use
Paediatric Committee
Paediatric Investigation Plan
Coordination and communication
Rewards and incentives
Symbol in the labels of medicinal products
Pharmacies
Pharmacy licences
How to apply for a pharmacy licence
Supervision Committee
Pharmacy tax
Special permits
How to apply for a special permit
Temporary special permit products
Manufacturing medicinal products
Schengen certificates
PIC/S GMP Guide
Dose-dispensing
Supervision
Pharmacovigilance
ICSR reporting to the EudraVigilance system
Pharmacovigilance inspections
Product defects
Summaries of risk management plans
Fimea's Instructions to the National Implementation of the Directive 2010/84/EU
Product-specific risk minimisation material
Clinical Drug Trials
Notification of a clinical trial - EudraCT
Serious Unexpected Adverse Reactions in Clinical Trials (SUSARs)
EU Regulation 536/2014
What's new
Advertising of medicinal products
Classification
Principles of classification
Classification application
List of medicines
After classification
Private imports of medicinal products
Pharmaceutical industry
Licenses
Local pharmaceutical wholesale license holders
Registered brokers of medicinal products
Good Laboratory Practice (GLP)
Mandatory reserve supplies
Reports on quantities to be stocked as mandatory reserve supplies
List of products to be stocked as mandatory reserve supplies
Application for exemption to maintain lower stock levels
Special arrangements for fulfilment of the obligation to maintain mandatory reserve supplies
Establishments
Supervision of blood activities
Supervising tissue establishments
Supervision of organ activity
Certificates of a Pharmaceutical Product (CPP)
Applying for an export certificate
Narcotics control
Additional information to be submitted with narcotics licence applications
Batch-specific control
GMP certificates
Laboratory of Fimea
National and international collaboration
Legislation
International and EU legislation
European Pharmacopoeia
National pharmacopoeia documents
To users of the Pharmacopoeia
CEP Procedure
International Non-proprietary Names for Pharmaceutical Substances (INN)
National laws
Administrative regulations
Normative guidelines
Other guidelines
Veterinary
Marketing authorisation procedures
Special permits for compassionate use
Applying for special permit
FAQ
A Questions and answers on how to fill in the form
B Questions and answers regarding the technical aspects of permit application
C Questions and answers regarding the decision and the processing of the application
D Other questions and answers
Lists of veterinary medicinal products
Adverse effects
Consumption of veterinary antimicrobials
The European Surveillance of Veterinary Antimicrobial Consumption ESVAC
Clinical trials on veterinary medicinal products
Immunological products
Withdrawal period and MRL
What is a withdrawal period?
MRL
Horses as food-producing animals
Private import
About us
Contact us
Change of address
Copyright
Contact
Personnel
Secure Mail
Coronavirus (COVID-19)
Frequently asked questions (COVID-19)
Adverse reactions reported on corona vaccines
What's new
News archive
Brexit
EU Presidency 2019
Open positions
Forms
Organisation
Strategy
Our goals
Strategic framework
International representation
Fimea committees
Publications
Fees
Estimated processing times
Frequently asked questions
Clinical drug trials
Generic medicines
Invoicing
Marketing authorisations
Summary of Product Characteristics is to be available also in Swedish
Narcotics control
New EudraVigilance -system
Open data
fimea.fi
About us
Frequently asked questions
Invoicing
Invoicing
Suomeksi
Frequently asked questions
Is it mandatory to notify Fimea of the post-authorization safety studies (i.e. PASS studies)?
How to submit a Swedish summary of product characteristics to Fimea?
What should be attached to the application for addition?
Is it possible to submit a Swedish summary of product characteristics for a product family in one application?
In connection with submitting a Swedish summary of product characteristics, is it possible to make changes also to the package leaflet?
In connection with submitting a Swedish summary of product characteristics, it possible to make other changes to the SPC?
Transferring marketing authorisation
How does the need for Swedish summary of product characteristics affect the centralised medicines?
Does the submission of the summary of product characteristics in Swedish apply also for veterinary medicinal products?
When should a summary of product characteristics in Swedish be submitted?
Page 1
1
Page 2
2
Page 3
3
Page 4
4
Page 5
5
Page 6
6
Page 7
7
Page 8
8
Page 9
9
Page 10
10
Previous
Previous
Next
Next
RSS
(Opens New Window)
(Opens New Window)
fimea.fi
About us
Frequently asked questions
Invoicing
Print
Close info
